JP2001039976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001039976A5 JP2001039976A5 JP2000151138A JP2000151138A JP2001039976A5 JP 2001039976 A5 JP2001039976 A5 JP 2001039976A5 JP 2000151138 A JP2000151138 A JP 2000151138A JP 2000151138 A JP2000151138 A JP 2000151138A JP 2001039976 A5 JP2001039976 A5 JP 2001039976A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- active ingredient
- preventing
- agent
- prophylactic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940043274 prophylactic drug Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Description
【特許請求の範囲】
【請求項１】
５−［４−（６−メトキシ−１−メチル−１Ｈ−ベンゾイミダゾール−２−イルメトキシ）ベンジル］チアゾリジン−２，４−ジオンの塩酸塩。
【請求項２】
請求項１に記載の化合物を有効成分して含有する医薬。
【請求項３】
請求項１に記載の化合物を有効成分として含有する、高血糖症予防薬又は治療薬。
【請求項４】
請求項１に記載の化合物を有効成分として含有する、耐糖能不全の予防薬又は治療薬。
【請求項５】
請求項１に記載の化合物を有効成分として含有する、糖尿病合併症の予防薬又は治療薬。
【請求項６】
請求項１に記載の化合物を有効成分として含有する、インスリン抵抗性に起因する疾病の予防薬又は治療薬。
【請求項７】
請求項１に記載の化合物を有効成分として含有する、インスリン抵抗性改善剤。
【請求項８】
インスリン抵抗性を改善するための医薬組成物を製造するための、請求項１に記載の化合物の使用。
【請求項９】
高血糖症の予防又は治療薬のための、請求項1に記載の化合物の使用。
【請求項１０】
糖尿病合併症の予防又は治療薬のための、請求項1に記載の化合物の使用。
【請求項１１】
請求項１に記載の化合物を有効成分として含有する、糖尿病の予防薬又は治療薬。
【請求項１２】
糖尿病を予防又は治療するための医薬組成物を製造するための、請求項１に記載の化合物の使用。
[Claims]
(1)
Hydrochloride salt of 5- [4- (6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2,4-dione.
(2)
A medicament comprising the compound according to claim 1 as an active ingredient.
(3)
A prophylactic or therapeutic drug for hyperglycemia, comprising the compound according to claim 1 as an active ingredient.
(4)
A prophylactic or therapeutic agent for impaired glucose tolerance comprising the compound according to claim 1 as an active ingredient.
(5)
A preventive or therapeutic drug for diabetic complications, comprising the compound according to claim 1 as an active ingredient.
6.
An agent for preventing or treating a disease caused by insulin resistance, comprising the compound according to claim 1 as an active ingredient.
7.
An insulin sensitizer comprising the compound according to claim 1 as an active ingredient.
Claim 8.
Use of a compound according to claim 1 for the manufacture of a pharmaceutical composition for improving insulin resistance.
9.
Use of the compound according to claim 1 for a prophylactic or therapeutic drug for hyperglycemia.
10.
Use of the compound according to claim 1 for an agent for preventing or treating diabetic complications.
11.
An agent for preventing or treating diabetes, comprising the compound according to claim 1 as an active ingredient.
12.
Use of a compound according to claim 1 for the manufacture of a pharmaceutical composition for preventing or treating diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000151138A JP2001039976A (en) | 1999-05-24 | 2000-05-23 | Hydrochloride of condensed heterocyclic compound |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11-143513 | 1999-05-24 | ||
| JP14351399 | 1999-05-24 | ||
| JP2000151138A JP2001039976A (en) | 1999-05-24 | 2000-05-23 | Hydrochloride of condensed heterocyclic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001039976A JP2001039976A (en) | 2001-02-13 |
| JP2001039976A5 true JP2001039976A5 (en) | 2007-07-12 |
Family
ID=26475217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000151138A Ceased JP2001039976A (en) | 1999-05-24 | 2000-05-23 | Hydrochloride of condensed heterocyclic compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001039976A (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1679074T3 (en) * | 2003-10-24 | 2011-03-21 | Santen Pharmaceutical Co Ltd | Therapeutic agent for keratoconjunctival disorders |
| KR20060118520A (en) | 2003-10-29 | 2006-11-23 | 산텐 세이야꾸 가부시키가이샤 | Therapeutic agent for keratoconjunctiva disorder |
| JP2006225382A (en) * | 2005-01-24 | 2006-08-31 | Sankyo Co Ltd | Production method for thiazolidinedione compound and its production intermediate |
| TW200637856A (en) | 2005-01-24 | 2006-11-01 | Sankyo Co | Process for producing thiazolidinedion compound and intermediate thereof |
| CN101336113B (en) | 2005-11-28 | 2015-07-29 | 千寿制药株式会社 | Comprise the medicine of PPAR agonist |
| JP2008044932A (en) * | 2006-07-21 | 2008-02-28 | Daiichi Sankyo Co Ltd | Composition containing thiazolidinedione compound |
| TW200816995A (en) * | 2006-08-31 | 2008-04-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition containing insulin sensitizers |
| KR101508020B1 (en) | 2007-05-21 | 2015-04-06 | 센주 세이야꾸 가부시키가이샤 | Pharmaceutical containing pparδ agonist |
-
2000
- 2000-05-23 JP JP2000151138A patent/JP2001039976A/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2001131722A (en) | 5- [4- (6-Methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidin-2,4-di hydrochloride having hypoglycemic activity | |
| JP2003501361A5 (en) | ||
| AU2002244860A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| CZ20032927A3 (en) | Treatment of type 2 diabetes mellitus using inhibitors of dipeptidyl peptidase IV | |
| JP2007533722A5 (en) | ||
| TWI255817B (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | |
| EP1803721A4 (en) | Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | |
| JP2010530431A5 (en) | ||
| JP2006502187A5 (en) | ||
| JP2007533733A5 (en) | ||
| JP2007519649A5 (en) | ||
| EP1806347A4 (en) | Aromatic-ring-fused pyrimidine derivative | |
| JP2004522714A5 (en) | ||
| MXPA03006217A (en) | Spaced drug delivery system. | |
| WO2009127974A3 (en) | Pharmaceutical formulation for treating cardiovascular disease | |
| JP2005526696A5 (en) | ||
| JP2001039976A5 (en) | ||
| EP1612208A3 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
| JP2002508372A5 (en) | ||
| US20160287549A1 (en) | Novel methods for treating neurodegenerative diseases | |
| JP2007538102A5 (en) | ||
| WO2005039578A3 (en) | Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof | |
| WO2007007757A1 (en) | Pharmaceutical composition containing pparϝ agonist | |
| BR112019026029A2 (en) | ORAL PHARMACEUTICAL FORMULATIONS OF REMOGLIFLOZINE | |
| JP2002532416A5 (en) | Pharmaceutical composition for enhancing glucose utilization in the brain |